What is LAR Octreotide?
LAR octreotide is a long-acting release formulation of the somatostatin analogue octreotide, designed for intramuscular injection every 4 weeks (monthly), used primarily for chronic management of neuroendocrine tumors and their associated hormonal syndromes. 1
Formulation and Administration
LAR octreotide is a depot formulation that provides sustained drug release over approximately 4 weeks, eliminating the need for multiple daily injections required with short-acting octreotide 1, 2. The drug is administered as an intramuscular injection at standard doses of 20-30 mg every 4 weeks 1, 3.
A critical pharmacokinetic consideration: therapeutic levels are not achieved for 10-14 days after LAR injection 1, 3. This delay necessitates bridging with short-acting octreotide (150-250 mcg subcutaneously 3 times daily) during treatment initiation or when rapid symptom control is needed 1.
Mechanism of Action
Octreotide LAR binds primarily to somatostatin receptor subtypes 2 (with high affinity) and 5 (with lower affinity) 2, 4. Through this binding, it:
- Inhibits release of growth hormone, glucagon, insulin, and various peptide hormones (gastrin, VIP, secretin, motilin, serotonin) 5
- Antagonizes growth factor effects on tumor cells 2, 4
- At very high doses, may induce apoptosis 2, 4
Clinical Indications
Neuroendocrine Tumors with Carcinoid Syndrome
Patients with metastatic NETs and carcinoid syndrome should be treated with octreotide LAR for symptom control (flushing, diarrhea) 1. Biochemical response rates of 30-70% and symptomatic control in the majority of patients have been demonstrated 2, 4.
Tumor Growth Control
In patients with clinically significant tumor burden or progressive disease, octreotide LAR is recommended to control tumor growth 1. The PROMID study showed median time to tumor progression of 14.3 months with octreotide LAR versus 6.0 months with placebo (P=0.000072) in metastatic midgut NETs 1, 3. After 6 months, stable disease was observed in 66.7% of octreotide LAR patients versus 37.2% with placebo 1.
The CLARINET study extended these findings to pancreatic and intestinal NETs with Ki-67 up to 10%, showing median PFS not reached with lanreotide (>27 months) versus 18 months with placebo 1.
Acromegaly
Octreotide LAR effectively controls growth hormone and IGF-1 secretion in approximately 55-70% of patients with acromegaly 6, 7, 8. It provides progressive control with long-term therapy up to 4 years 6.
Dosing Strategies
Standard dosing: 20-30 mg intramuscularly every 4 weeks 1, 3, 1.
Dose escalation strategies when standard dosing is insufficient:
- Increase dose above 30 mg every 4 weeks 1
- Shorten injection interval to every 3 weeks or even every 2 weeks 9
- Add short-acting octreotide 150-250 mcg subcutaneously 3 times daily for breakthrough symptoms 1, 3
Real-world data shows 19% of LAR prescriptions use above-label maximum doses, with dose escalation occurring in 22.3% of NET/carcinoid syndrome patients, primarily for symptom control (50.9%) 10.
Important Clinical Considerations
Bridging therapy is essential: Because therapeutic levels take 10-14 days to achieve, short-acting octreotide must be continued during this period when switching from immediate-release formulations 1, 3.
Carcinoid crisis prevention: In high-stress situations (surgery, hepatic artery embolization), patients require increased coverage with short-acting octreotide by intravenous administration (50 mcg/hour), starting 12 hours before, during, and 48 hours after procedures 4.
Cardiac monitoring: Patients with carcinoid syndrome and 5-HIAA levels ≥300 mcmol (57 mg) over 24 hours plus ≥3 flushing episodes daily should undergo cardiology consultation and echocardiogram to assess for carcinoid heart disease 1.
Adverse Effects
The drug is generally well tolerated 1, 2, 4. Common adverse events include:
- Gastrointestinal symptoms (30% incidence): usually transient and mild-to-moderate 6
- Gallbladder abnormalities (sediment, sludge, gallstones): occur with long-term use but only 1% become symptomatic 6
- Glucose metabolism alterations: approximately 15% develop hyperglycemia, usually mild 6
- Fat malabsorption, vitamin A and D malabsorption 4
Treatment discontinuations due to adverse events are uncommon 11.
Advantages Over Short-Acting Formulations
Monthly administration dramatically improves quality of life and compliance compared to 2-3 daily subcutaneous injections 2, 4. Long-acting formulations have comparable or better efficacy than short-acting octreotide and are now considered the standard of care for symptomatic treatment of NETs 2.